Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: A randomized, double-blind, placebo-controlled trial in Chinese males and females

How university students view human papillomavirus (HPV) vaccination: A cross-sectional study in Jinan, China

“…[9][10][11] In China, good tolerability and cost-effectiveness of HPV vaccine has been reported among 9-15 years old males and 9-45 years old females. 12 Both the World Health Organization (WHO) and the US Food and Drug Administration (FDA) recommends the HPV vaccine to be used among men and women aged 9 through 26. 13,14 Despite of the availability of HPV vaccination programs in over 50 countries, this vaccine is still yet to be approved in China.…”

Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa

“…[12][13][14][15][16][17] Prior to the current study, all studies of the immunogenicity, safety, and efficacy of the qHPV vaccine had been conducted in North America, Latin America, Europe, Asia, and Oceania. 12,13,[18][19][20][21][22][23][24] The efficacy and/or immunogenicity of vaccines and the pathogenicity of the organisms that they target can differ in subpopulations defined by race/ethnicity, behavior, age, and socioeconomic status. 24 Data from the qHPV vaccine program to date support no clinically relevant impact of these baseline covariates on responses to the qHPV vaccine in a sub-Saharan African population.…”

Prevention of human papillomavirus (HPV) infection and cervical cancer in China: How does HPV vaccination bring about benefits to Chinese women?

“…High antibody levels were observed for each of the four HPV types and sero-conversion was > 96%. (Li et al, 2010) Cost-effectiveness of cervical cancer prevention and control strategies…”

“…Only 6% of women were willing to pay more than US $300 for the vaccine. and safety of the vaccines, cost-effectiveness of cervical cancer prevention and control strategies Sexual behavior of the population, and knowledge and attitudes towards the vaccines and HPV-related diseases are also important (46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57). In China, the prevalence of HPV 16 and 18, which are prevented by the current vaccines, is generally high, while there is a huge geographic diversity of the prevalence of oncogenic HPV types.…”

“…The infection can be detected in more than 95% of carcinoma issues (2). So far, more than 100 different HPV genotypes have been detected, and among them type 16,18,31,33,35,39,45,51,52,56,58,59, and 68 are a high-risk for cervical carcinoma. The most common genotypes among infected women are 16, 18, 31, 58, and 52, accounting for approximately half of HPV infections (3).…”